Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III Trial

NCT05157776 is registered in ClinicalTrials.gov with Tongji University as lead sponsor.

NCT NCT05157776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05157776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Sintilimab and Platinum-based Chemotherapy for Resectable Locally Advanced NSCLC Harboring no Driver Mutations: A Prospective, Randomized, Multicenter Phase III Trial
Lead sponsor
Tongji University
Phase
Phase 3
Overall status
Unknown status
Start date
October 28, 2021
Completion date
October 31, 2025
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk negative nsclc, egf-r negative non-small cell lung cancer, nsclc, stage iiia